REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children
This study has been completed.
Sanofi Pasteur, a Sanofi Company
First Posted: March 14, 2007
Last Update Posted: September 11, 2017
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Gajdos V, Soubeyrand B, Vidor E, Richard P, Boyer J, Sadorge C, Fiquet A. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age. Hum Vaccin. 2011 May;7(5):549-56. Epub 2011 May 1.